Company: PTPI
Filing Date: 2025-02-10
Form Type: S-1/A
Source: 0001410578-25-000108
Chunk: 264

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-10
Form: S-1/A
Chunk 264
---
   | $ |   654,774 |
| 2025                      |   | ​ | 1,754,329 |
| 2026                      |   | ​ | 1,442,186 |
| 2027                      |   | ​ | 1,212,871 |
| 2028                      | ​ | ​ |   996,636 |
| Thereafter                |   | ​ |   765,091 |
| Total                     | ​ | $ | 6,825,887 |

The intangible assets held by the Company are the Stendra® product, Timm Medical product, and PTV product and are being amortized over their estimated useful lives of , , and , respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of September 30, 2024, are $ million, $ million and $ million, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of December 31, 2023, were $ million, $ million and $ million, respectively. During the nine months ended September 30, 2024, and 2023, respectively, the Company recorded $ million and $ million of amortization expense. During the three months ended September 30, 2024, and 2023, respectively, the Company recorded $ million and $ million of amortization expense.

7) Accrued Expenses

Accrued expenses are comprised of the following:

| ​                         | ​ 
 ​ | ​ |                  ​ 
 September 30, 2024 | ​ | ​ |                 ​ 
 December 31, 2023 |
|:--------------------------|:--|:--|-------------------:|:--|:--|------------------:|
| Accrued product returns   | ​ | $ |          5,299,261 | ​ | $ |         4,178,176 |
| Accrued contract rebates  | ​ |   |             96,465 | ​ | ​ |           128,562 |
| Due to 3PL/Wholesalers    | ​ |   |             62,284 | ​ | ​ |            75,727 |
| Accrued bonuses           | ​ | ​ |            501,988 | ​ | ​ |           665,184 |
| Accrued professional fees | ​ |   |                  — | ​ | ​ |